Chromatin/Epigenetics


Epigenetics is the heritable modifications in gene expression that is not associated with changes in DNA sequence. Epigenetic modifications occur mostly on DNA or on the histone octamer. There are several types of epigenetics modifications, DNA methylation by DNA-methyl transferase (DNMT) and covalent modification of histones (e.g. acetylation, methylation, phosphorylation and ubiquitination). Histone acetylation by histone acetyltransferases (HATs) is involved in transcriptional activation, whereas histone deacetylation by histone deacetylases (HDACs) is connected with transcriptional repression. Histone demethylation is associated with lysine-specific demethylase (LSD) and JmjC domain containing histone demethylase (JHDM).
The nucleosome is consisted of four histone proteins (H2A, H2B, H3, and H4), they are primary building block of chromatin. The addition and removal of specific chemical groups refers to as epigenetic marks, it regulates chromatin structure and affects gene expression. Moreover, RNA is intimately involved in the formation of a repressive chromatin state.
Epigenetic mechanism responds to environmental changes at the cellular level and thus influences cellular plasticity. Chromatin and epigenetic regulation play a significant role in the programming of the genome during development and stress response, defects in epigenetics can lead to cancer, inflammation and metabolic disorders etc.
-
A8964 SETDB1-TTD-IN-1Summary: A SETDB1 activator that binds the tandem Tudor domain (TTD) and enhances SETDB1 methyltransferase activity for epigenetic regulation and cancer -
A8965 VTP50469Summary: A highly selective, orally bioavailable Menin-MLL interaction inhibitor -
A8967 EZM0414 TFA -
A8970 Itacitinib adipate -
A8973 EZM0414Summary: A selective SETD2 methyltransferase inhibitor for lymphoma -
A8988 PARP10-IN-2 -
A8992 3-Methoxybenzamide -
A9017 PARP10-IN-3 -
A9031 A-3 hydrochloride -
A9038 EML 425

